FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:200-203 January 10, 2008 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

To the Editor: Tuberous sclerosis is an autosomal dominant disorder characterized by hamartomatous growths in many organs and caused by inherited mutations of the TSC1 or TSC2 gene. Acquired (somatic) mutations of either gene occur within pathologic cells in patients with sporadic lymphangioleiomyomatosis. Renal angiomyolipomas occur in both disorders, resulting in substantial morbidity and mortality.¹ The proteins TSC1 and TSC2 regulate signaling through the mammalian target of rapamycin (mTOR) pathway to control processes including growth, cell-cycle progression, apoptosis, and autophagy. Constitutive activation of mTOR and its downstream targets occurs in lesions associated with tuberous sclerosis or lymphangioleiomyomatosis, suggesting that mTOR . . . [Full Text of this Article]

Related Letters:

Sirolimus for Lymphangioleiomyomatosis Lesions
Egan J. J., Remund K. F., Corris P., Bissler J. J., Young L. R., McCormack F. X.
Extract | Full Text | PDF  
N Engl J Med 2008; 358:1963-1964, May 1, 2008. Correspondence

This article has been cited by other articles:

• Shackelford, D. B., Vasquez, D. S., Corbeil, J., Wu, S., Leblanc, M., Wu, C.-L., Vera, D. R., Shaw, R. J. (2009). mTOR and HIF-1{alpha}-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc. Natl. Acad. Sci. USA 106: 11137-11142 [Abstract] [Full Text]  
• Bonnet, C. S., Aldred, M., von Ruhland, C., Harris, R., Sandford, R., Cheadle, J. P. (2009). Defects in cell polarity underlie TSC and ADPKD-associated cystogenesis. Hum Mol Genet 18: 2166-2176 [Abstract] [Full Text]  
• Hartman, T. R., Liu, D., Zilfou, J. T., Robb, V., Morrison, T., Watnick, T., Henske, E. P. (2009). The tuberous sclerosis proteins regulate formation of the primary cilium via a rapamycin-insensitive and polycystin 1-independent pathway. Hum Mol Genet 18: 151-163 [Abstract] [Full Text]  
• Grunfeld, J.-P. (2009). Towards Therapy in Genetic Kidney Diseases: Hopes and Uncertainties. CJASN 4: 18-21 [Full Text]  
• Rosner, M., Hengstschlager, M. (2008). Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1. Hum Mol Genet 17: 2934-2948 [Abstract] [Full Text]  
• Egan, J. J., Remund, K. F., Corris, P., Bissler, J. J., Young, L. R., McCormack, F. X. (2008). Sirolimus for Lymphangioleiomyomatosis Lesions. NEJM 358: 1963-1964 [Full Text]  
• (2008). Sirolimus for Angiomyolipoma and Lymphangioleiomyomatosis. JWatch Neurology 2008: 1-1 [Full Text]  
• Paul, E., Thiele, E. (2008). Efficacy of Sirolimus in Treating Tuberous Sclerosis and Lymphangioleiomyomatosis. NEJM 358: 190-192 [Full Text]